What is CONMED's D&A?

CONMED (CNMD) reported D&A of $4.17M in Q1 2026.

How has CONMED's D&A changed year-over-year?

CONMED's D&A decreased by 1.4% year-over-year, from $4.24M to $4.17M.

What is the long-term trend for CONMED's D&A?

Over 4 years (2021 to 2025), CONMED's D&A has grown at a 1.0% compound annual growth rate (CAGR), from $16.49M to $17.14M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

CONMED CNMD D&A

D&A at other companies

Johnson & JohnsonJNJ

$2B+13.1%

Boston ScientificBSX

$351M+8.0%

VericelVCEL

$3.27M+21.6%

OSI SystemsOSIS

$9.52M-9.9%

Zimmer Biomet HoldingsZBH

$270M+6.1%

MedtronicMDT

$716M-14.8%

Other financials

Income statement

See full

Revenue$317.0M-1.3%

Gross profit$183.4M+3.2%

Operating income$25.4M+59.3%

Net income$13.8M+129%

EPS (diluted)$0.45+137%

Balance sheet

See full

Cash & equivalents$35.0M-1.3%

Total debt$862.6M-3.6%

Total equity$1.0B+4.1%

Total assets$2.3B+0.8%

Cash flow

See full

Operating cash flow$13.5M-67.6%

CapEx$2.9M-23.5%

Free cash flow$10.6M-72.0%

Valuation

See full

Market cap$1.04B-35.6%

Enterprise value$1.87B-24.5%

P/E19×+5.4×

P/S0.8×-0.5×

Profitability

See full

Gross margin55.2%-1.0pp

Operating margin8.2%-5.6pp

Net margin4%-5.0pp

FCF margin9%-3.5pp

Returns & leverage

See full

Return on equity5.5%-7.5pp

Debt / equity0.8×-0.1×

Current ratio2.3×0.0×

Where this comes from

Reported directly by CONMED in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: CONMED’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about CONMED's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is CONMED's D&A?: CONMED (CNMD) reported D&A of $4.17M in Q1 2026.
How has CONMED's D&A changed year-over-year?: CONMED's D&A decreased by 1.4% year-over-year, from $4.24M to $4.17M.
What is the long-term trend for CONMED's D&A?: Over 4 years (2021 to 2025), CONMED's D&A has grown at a 1.0% compound annual growth rate (CAGR), from $16.49M to $17.14M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.